Thursday, 14th March 36th TROG Cancer Research Annual Scientific Meeting 2024

This session is sponsored by:

• The GETUG Strategy of clinical trials in oligometastatic prostate cancer - Stéphane SUPIOT
• FASTRACK  - Multicentre Phase II Trial of SABR for Primary Kidney Cancer - Shankar Siva
• TROG 19.06 DECREASE: DarolutamidE + Consolidation RadiothErapy in Advanced proStatE cancer detected by PSMA (Cat A, Open) - Shankar Siva
• TROG 18.01 NINJA: Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation (Cat A, Open) - Jarad Martin
• TD 23.03 2SHOTS; 2-fraction Stereotactic radiotherapy Of the ProState  (Cat A, New Proposal) - Wee Loon Ong
• TD 23.03 2SHOTS: Discussant  - Eric Wegener
• TD 23.01 REMASTER; REduced MArgin STEReotactic body radiotherapy for prostate cancer: A phase III randomised trial (Cat A, In development) - Muhammad Ali
• PEARLS: A phase II/III trial of Primary radiothErapy for Androgen sensitive pRostate cancer patients with Lymph nodeS  - Niluja Thiru
• Genitourinary (GU) Working Party update - Wee Loon Ong

• Seeing Biology: Using novel PET tracers to develop personalised, biologically driven approaches to radiation therapy treatment  - Fiona Hegi-Johnson
• Harnessing cell death mechanisms after ablative radiotherapy to enhance immunotherapy synergy - Harriet Gee
• Balancing data collection burden for participating centres and comprehensive utilization of clinical trial data : An NCI perspective - Stephen Kry
• Machine learning simulation of targeted ablation for oligoprogressive metastatic prostate cancer - Timothy G Perk

Panel Session with:

Dr Fiona Hegi-Johnson, Peter MacCallum Cancer Centre;

Dr Harriet Gee, Westmead Hospital;

Prof Stephen Kry, MD Anderson Cancer Centre;

Timothy G Perk, AIQ Solutions

• Computational analysis and artificial intelligence approaches for the FET PET in Glioblastoma (FIG) Trial - TROG 18.06 - Nathaniel Barry
• The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small cell lung cancer - Neil D Wallace
• Using conceptual frameworks to guide the selection of Patient Reported Outcome Measures in cancer clinical trials: A CQUEST Resource - Carrie-Anne Ng
• The impact of age on survival after chemoradiotherapy for stage III NSCLC - Neil Wallace
• Deep learning-based automated assessment of prostate motion during radiotherapy treatment - Ryan Motley
• Clinical evaluation of a real-time treatment verification system for stereotactic body radiotherapy - Jose A Baeza-Ortega
• Treatment plan quality review with knowledge‑based planning in the TROG 18.01 NINJA trial - Alisha Moore

• Moderately hypofractionated chemoradiation followed by immunotherapy for inoperable Stage 3 Non-Small Cell Lung Cancer given with radical intent in older adults (MODERN-LUNG): a randomised trial - Jane Ludbrook
• TD 24.01 MODERN-LUNG: Discussant  - Margot Lehman
• TD 21.08 VITaL; The Ventilation Imaging for Thoracic Lung cancer radiation therapy trial (Cat C, In development)  - Paul Keall
• PRIME-LUNG: A randomised phase 3 trial of up-front stereotactic radiotherapy before standard-of-care systemic therapy in advanced lung cancer (Cat C, In development) - Shankar Siva
• TD 21.09 OCTAVO; A phase II study of consolidation radiation for induced oligo-persistent disease following initial immunotherapy (Cat C, In development)  - Eric Hau
• TROG 20.01 CHEST RT: A phase II study of carboplatin and etoposide chemotherapy, durvalumab with or without thoracic radiotherapy in the first line treatment of patients with extensive-stage small-cell lung cancer (Cat A, Open)  - Eric Hau
• TROG 17.02 OUTRUN Randomised phase II trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated NSCLC with brain metastases (Cat A, Open);  Preliminary results +  Cognitive Function analysis  - Yu Yang Soon
• Impact of SABR on Pulmonary Function: An Analysis of the TROG13.01 (SAFRON II) trial - Nicholas Bucknell
• Trial Concept Discussion; Ultracentral  - Lucinda Burke
• 4D MRI for lung tumour motion assessment - Jonathan Goodwin
• Overview of the National Lung Cancer Screening Program - Scott H Twaddell
• Lung Working Party Update - Yu Yang Soon

2:50 PM Panel Discussion; Opportunities for TROG research with the implementation of National Lung Cancer Screening Program:

Dr Scott Twaddell, John Hunter Hospital;

Sue McCullough AM, TOGA; 

A/Prof Harriet Gee, Westmead Hospital;

Dr Peng Seah, John Hunter Hospital

• Tackling financial toxicity: Isn’t it just common sense? - Deme Karikios
• A new Patient Reported Measure for use in clinical trials comparing shorter fractionation with conventional schedules: measuring RT related "inconvenience" - Puma Sundaresan
• Symptoms in Cancer Survivorship: How patient-reported outcomes can guide intervention research - Haryana Dhillon
• Multidisciplinary, patient informed and patient centred research:The "problem" that informed the "Remove the mask" program of research  - Puma Sundaresan
• Multidisciplinary, patient informed and patient centred research: Using technology to "Remove the mask" - Youssef Y Ben Bouchta

Panel Discussion with:

Dr Deme Karikios, Nepean Cancer Car Centre

A/Prof Puma Sundersan, NSW Health

A/Prof Haryana Dhillion, University of Sydney

Dr Youssef Ben Bouchta, University of Sydney

Location: The Arena, Newcastle Exhibition & Convention Centre (The NEX)

309 King St, Newcastle West NSW 2302

Dress Code: Black Tie on the Beach